IMUGENE LIMITED ORDINARY (IMU) Short Interest
IMUGENE LIMITED ORDINARY (ASX:IMU) had 1.73% of shares reported as short positions as of 4 June 2026, representing 7,214,681 shares. IMUGENE LIMITED ORDINARY operates in the Pharmaceuticals, Biotechnology & Life Sciences industry. Source: ASIC short position report (T+4 delay).
- Short interest
- 1.73%
- Reported positions
- 7,214,681
- Industry
- Pharmaceuticals, Biotechnology & Life Sciences
- As of
- 4 June 2026
Source: official ASIC short position report, T+4 delay. Methodology · Disclaimer — not financial advice.
IMU
Imugene
Imugene is a clinical-stage biotechnology company focused on developing novel immunotherapies for cancer treatment. Their pipeline includes B-cell immunotherapies and oncolytic virotherapy technologies designed to activate the immune system against cancer cells. Imugene aims to improve the lives of cancer patients by creating more effective and tolerable treatments.